Hong Kong stocks surge | China Antibody-B(03681.HK) up more than 8%, planning to issue new shares at a discount of about 16.12% to raise net proceeds of 369 million Hong Kong dollars for use in SM03 clinical trials, etc.

According to the CNBC APP, China Antibody-B (03681.HK) has risen by more than 8%, as of the time of the announcement, it has increased by 8.68%, reaching 2.63 Hong Kong dollars, with a transaction volume of 31.73 million Hong Kong dollars.